首頁 > 市場調查報告書 > 製藥

動物用醫藥

市場調查報告書

商品編碼

1577001

伴侶獸藥市場、機會、成長動力、產業趨勢分析與預測，2024-2032

Companion Animal Drugs Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年08月02日 | 出版商:

Global Market Insights Inc. | 英文 145 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023 年，全球伴侶動物藥物市場價值為196 億美元，2024 年至2032 年間將以7.5% 的複合年成長率成長，原因是可在動物和人類之間傳播的人畜共患疾病的患病率不斷上升。隨著人們對這些疾病的認知不斷提高，寵物主人和獸醫越來越關注預防保健和治療，以確保動物和人類的健康。此外，人們對整體動物健康的認知不斷增強，以及及時獸醫護理的重要性也進一步增加了對伴侶動物藥物的需求。對預防和治療的高度重視將顯著擴大市場。

伴侶動物藥品產業根據產品、動物類型、給藥途徑、配銷通路和地區而分散。

由於對寵物感染、過敏和慢性病等各種疾病的有效治療的需求不斷成長，藥品領域在 2023 年將保持 54.2% 的佔有率。該細分市場受益於獸藥的不斷進步以及寵物主人對動物醫療保健重要性的認知不斷提高。隨著越來越多的寵物主人優先考慮預防和治療護理，解決廣泛健康問題的創新藥物的需求將主導市場。

到 2032 年，由於養狗人數眾多以及獸醫護理需求不斷成長，狗類市場將以 7.4% 的複合年成長率成長。狗通常需要定期治療感染、過敏和關節炎等慢性疾病，這使它們成為獸藥公司的主要關注點。隨著人們越來越重視預防保健、疫苗接種和先進治療，對專門針對狗的藥物的需求將保持強勁，從而促進市場擴張。

由於其完善的寵物醫療基礎設施、較高的寵物擁有率以及人們對動物健康意識的不斷增強，到 2032 年，北美地區的市場規模將擴大到 145 億美元。該地區受益於強大的獸藥公司和先進的研究設施，推動了寵物藥物的創新。此外，寵物護理支出的增加和寵物保險的廣泛普及進一步支持了市場的成長。北美強大的獸醫生態系統使其成為伴侶動物藥品市場的顯著貢獻者。

產業格局，2018 - 2032
產業影響力
- 成長動力
  - 全球寵物保險需求激增
  - 伴侶動物肥胖率上升
  - 增加政府對全球寵物照護的支持
  - 對網路獸藥局的需求不斷成長
- 產業陷阱與挑戰
  - 與伴侶動物藥物相關的高成本
成長潛力分析
監管環境/政策環境
- 美國
- 歐洲
- 亞太
差距分析
消費者行為趨勢
產業生態系統
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
- Zoetis Inc.
- Boehringer Ingelheim International GmbH
- Elanco Animal Health Incorporated
公司市佔率分析
公司矩陣分析
戰略儀表板

第 5 章：市場估計與預測：按產品分類，2018 - 2032 年

主要趨勢
藥品
- 抗寄生蟲藥
- 消炎劑
- 抗感染藥
- 皮質類固醇
- 鎮靜劑
- 心血管藥物
- 胃腸道藥物
疫苗
- 改良活疫苗 (MLV)
- 去活化去活化疫苗
- 重組疫苗
藥用飼料添加劑
- 抗生素
- 維生素
- 胺基酸
- 酵素
- 抗氧化劑
- 益生元和益生菌
- 礦物質
- 碳水化合物
- 丙二醇

第 6 章：市場估計與預測：按動物類型，2018 年 - 2032 年

主要趨勢
狗
貓
馬匹
其他動物

第 7 章：市場估計與預測：按管理途徑，2018 年 - 2032 年

主要趨勢
口服
可注射
專題
其他給藥途徑

第 8 章：市場估計與預測：按配銷通路，2018 年 - 2032 年

主要趨勢
獸醫院藥房
零售藥房
電子商務

第 9 章：市場估計與預測：按地區分類，2018 年 - 2032 年

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 波蘭
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 台灣
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 南非
- 海灣合作理事會國家
- 以色列
- 中東和非洲其他地區

第 10 章：公司簡介

Agrolabo SpA
Boehringer Ingelheim International GmbH
Ceva Sante Animale
Chanelle Pharma
Dechra Pharmaceuticals PLC
Elanco Animal Health Incorporated
Endovac Animal Health
HIPRA
Indian Immunologicals Ltd.
Merck and Co., Inc.
Norbrook
Symrise
Vetoquinol
Virbac
Zoetis Inc.

簡介目錄

Product Code: 4981

The Global Companion Animal Drugs Market was valued at USD 19.6 billion in 2023 and will grow at a 7.5% CAGR between 2024 and 2032, attributed to the rising prevalence of zoonotic diseases, which can be transmitted between animals and humans. As awareness of these diseases increases, pet owners and veterinarians are focusing more on preventive care and treatments to safeguard animal and human health. Also, growing awareness of overall animal health and the importance of timely veterinary care is further boosting demand for companion animal drugs. This heightened focus on prevention and treatment will expand the market significantly.

The companion animal drugs industry is fragmented based on product, animal type, route of administration, distribution channel, and region.

The drugs segment upheld a 54.2% share in 2023 due to the growing demand for effective treatments for various conditions, such as infections, allergies, and chronic diseases in pets. This segment benefits from continuous advancements in veterinary pharmaceuticals and increasing awareness among pet owners about the importance of medical care for animals. As more pet owners prioritize preventive and therapeutic care, the need for innovative drugs to address a wide range of health issues will dominate the market.

The dog segment will grow at a 7.4% CAGR through 2032, driven by the high number of dog owners and the increasing demand for veterinary care. Dogs often require regular treatments for infections, allergies, and chronic conditions like arthritis, making them a primary focus of veterinary pharmaceutical companies. With a growing emphasis on preventive care, vaccinations, and advanced treatments, the demand for drugs specifically tailored to dogs will remain strong, contributing to the market expansion.

North America will expand to USD 14.5 billion by 2032, owing to its well-established pet healthcare infrastructure, high pet ownership rates, and growing awareness of animal health. The region benefits from a strong presence of veterinary pharmaceutical companies and advanced research facilities, driving innovation in pet medications. Besides, increasing expenditures on pet care and the widespread availability of pet insurance further support market growth. North America's robust veterinary ecosystem makes it a notable contributor to the companion animal drugs market.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry landscape, 2018 - 2032 (USD Million)
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Surging demand for pet insurance policies worldwide
  - 3.2.1.2 Rising rate of obesity in companion animals
  - 3.2.1.3 Increasing government support for pet care across the globe
  - 3.2.1.4 Growing demand for online veterinary pharmacies
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High cost associated with companion animal drugs
3.3 Growth potential analysis
3.4 Regulatory landscape/policy landscape
- 3.4.1 U.S.
- 3.4.2 Europe
- 3.4.3 Asia-Pacific
3.5 Gap analysis
3.6 Consumer behavior trends
3.7 Industry ecosystem
3.8 Porter's analysis
3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
- 4.1.1 Zoetis Inc.
- 4.1.2 Boehringer Ingelheim International GmbH
- 4.1.3 Elanco Animal Health Incorporated
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2018 - 2032 ($ Mn)

5.1 Key trends
5.2 Drugs
- 5.2.1 Antiparasitic
- 5.2.2 Anti-inflammatory
- 5.2.3 Anti-infectives
- 5.2.4 Corticosteroids
- 5.2.5 Tranquilizers
- 5.2.6 Cardiovascular drugs
- 5.2.7 Gastrointestinal drugs
5.3 Vaccines
- 5.3.1 Modified live vaccines (MLV)
- 5.3.2 Killed inactivated vaccines
- 5.3.3 Recombinant vaccines
5.4 Medicated feed additives
- 5.4.1 Antibiotics
- 5.4.2 Vitamins
- 5.4.3 Amino acids
- 5.4.4 Enzymes
- 5.4.5 Antioxidants
- 5.4.6 Prebiotics and probiotics
- 5.4.7 Minerals
- 5.4.8 Carbohydrates
- 5.4.9 Propandiol

Chapter 6 Market Estimates and Forecast, By Animal Type, 2018 - 2032 ($ Mn)

6.1 Key trends
6.2 Dogs
6.3 Cats
6.4 Horses
6.5 Other animals

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Mn)

7.1 Key trends
7.2 Oral
7.3 Injectable
7.4 Topical
7.5 Other routes of administration

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)

8.1 Key trends
8.2 Veterinary hospital pharmacy
8.3 Retail pharmacy
8.4 E-commerce

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Poland
- 9.3.7 Netherlands
- 9.3.8 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Taiwan
- 9.4.7 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 GCC Countries
- 9.6.3 Israel
- 9.6.4 Rest of Middle East and Africa